^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Excerpt:
Eligible patients with advanced solid tumors received escalating doses of JNJ-42756493 from 0.5 to 12 mg administered continuously daily or JNJ-42756493 10 or 12 mg administered intermittently (7 days on/7 days off)….Two other confirmed PRs were observed in a patient with glioblastoma (by the Revised Assessment for Neuro-Oncology Criteria) at 9 mg daily and a patient with endometrial cancer at the 12-mg intermittent dose with FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 (FGFR2-BICC1 and FGFR2-OFD1 occurred at similar frequency), respectively...
DOI:
10.1200/JCO.2014.60.7341
